Serotonergic Dynamics in Levodopa-Induced Dyskinesia

Levodopa-induced dyskinesia (LID) arises from chronic administration of levodopa in Parkinson’s disease, manifesting as involuntary, hyperkinetic movements. Central to LID is the capacity of serotonergic neurons to convert exogenous levodopa into dopamine and release it without the normal autoregulatory feedback mechanisms present in dopaminergic terminals. This “false neurotransmission” leads to pulsatile, unbuffered surges of dopamine in the striatum, perturbing basal ganglia circuits and driving maladaptive plasticity within motor pathways. Electrophysiological studies reveal exaggerated gamma oscillations and dysregulated phase–amplitude coupling in cortico‐striatal networks during dyskinetic states. At the receptor level, altered sensitivity of 5-HT1A and 5-HT1B subtypes, together with changes in serotonin transporter function, modulate both the onset and severity of dyskinesia. Understanding these dynamics has spurred interest in targeting serotonergic mechanisms—either by receptor agonists to reinstate feedback control or by multimodal compounds that normalise synaptic serotonin and dopamine balance. Such approaches hold promise to attenuate dyskinetic movements while preserving the antiparkinsonian efficacy of levodopa, offering a refined strategy for long‐term management of motor complications.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Serotonergic Dynamics in Levodopa-Induced Dyskinesia publication trend

The graph below shows the total number of articles in serotonergic dynamics in levodopa-induced dyskinesia across all publications each year (not limited to Nature Index journals).

Technical terms

Levodopa-induced dyskinesia (LID): Involuntary, hyperkinetic movements emerging from pulsatile dopamine release following chronic levodopa treatment.

False neurotransmission: Release of dopamine by serotonergic neurons lacking dopaminergic autoregulatory controls, leading to unbuffered synaptic surges.

Autoreceptor: A presynaptic receptor that regulates its own neurotransmitter’s synthesis and release via feedback inhibition.

Phase–amplitude coupling (PAC): A measure of interaction between the phase of low-frequency oscillations and the amplitude of high-frequency oscillations in neural circuits.

Gamma oscillations: High-frequency brain rhythms (30–100 Hz) associated with motor control and cognitive processing, exaggerated in dyskinetic states.

References

1. Serotonin as a biomarker of toxin-induced Parkinsonism. Molecular Medicine (2024).
2. Broad Serotonergic Actions of Vortioxetine as a Promising Avenue for the Treatment of L-DOPA-Induced Dyskinesia. Cells (2023).
3. Eltoprazine modulated gamma oscillations on ameliorating L‐dopa‐induced dyskinesia in rats. CNS Neuroscience & Therapeutics (2023).
4. L-DOPA in Parkinson’s Disease: Looking at the “False” Neurotransmitters and Their Meaning. International Journal of Molecular Sciences (2019).